hims hers glp 1 & swings to a loss in Q1 amid shift in GLP-1 strategy Hims & Hers expands weight
Description
10.1016/j.ogla.2024.03.005
Tirzepatide was initially approved for type 2 diabetes (Mounjaro), and it is now also approved for long-term weight loss in adults with obesity or overweight with weight-related health conditions (Zepbound)
Publisher Diabetes, Obesity and Metabolism Accessed Jun 27, 2026 Study type Systematic Review Limitations: A review can frame the issue, but exercise and nutrition decisions still belong in individualized care
GDUFA III Performance Goals and Program Enhancement Commitments
doi:10.2174/1389450043345245 184
